Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium tanshinone IIA sulfonate for coronary microcirculation protection in acute coronary syndrome patients undergoing PCI
ChiCTR1800020340Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sodium tanshinone IIA sulfonate in acute coronary syndrome (ACS) (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Corrected TIMI frame count and Area under the curve of CK-MB. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
sodium tanshinone IIA sulfonate
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR1800020340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020340.